All terms in DRUGBANK

Label Id Description
Ranolazine DB00243 [Ranolazine is an acetanilide and piperazine derivative that is used for the treatment of angina.[L3580] It was originally approved by the FDA in 2006.[L5440]]
Cladribine DB00242 [An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.]
Benzylmorphine DB01573
Dobesilic acid DB13529
Althea root DB13525
Avadomide DB14857 [Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).]
PF-05089771 DB14856 [PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).]
Pentaerithrityl DB13526
Fosifloxuridine nafalbenamide DB14859 [Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).]
Proglumetacin DB13527
Chlormadinone DB13528
Tadekinig alfa DB14858 [Tadekinig alfa is under investigation in clinical trial NCT03113760 (Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency).]
Alipogene tiparvovec DB13521
Myrcludex B DB14853 [Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D).]
PRM-151 DB14852 [PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).]
Mebicar DB13522
2-(aminomethyl)phenol DB14855 [2-(aminomethyl)phenol is under investigation in clinical trial NCT03556319 (2-HOBA: Multiple Dosing Study in Older Adults).]
Veralipride DB13523
Propyphenazone DB13524
TC-6987 DB14854 [TC-6987 is under investigation in clinical trial NCT01296087 (TC-6987 for the Treatment of Mild to Moderate Asthma).]